Why aren't we all doing ultrasound?

Authors:

Abstract
Musculoskeletal ultrasound (MUS) is potentially the most exciting development in clinical rheumatology practice in recent years. It is readily accessible, patient friendly and relatively inexpensive. It can be used to detect small joint effusions and thus increase the accuracy of diagnostic aspiration and therapeutic injection [1]. It is more sensitive than clinical examination in detecting enthesitis [2] and seven times more sensitive than X-ray in detecting small erosions [3]. It is in the area of detection of early synovitis, however, where the greatest potential lies. MUS can detect subclinical inflammation and is comparable with MRI in this respect [4, 5], a phenomenon that may explain the apparent dissociation between clinical remission and joint damage in RA [6]. Power Doppler MUS can also be used to monitor response to biologic therapy [7] facilitating more rational decision making in the use of these very expensive treatments. These developments have stimulated a greatly increased interest in MUS, which can be gauged by the demand for courses organized by the British Society for Rheumatology (BSR) or the European League Against Rheumatism (EULAR) and the increase in publications related to this topic in recent years.

This publication has 15 references indexed in Scilit: